(ALK-B) ALK-Abelló - Ratings and Ratios

ALK-Abelló A/S is a global leader in allergy immunotherapy, operating across Europe, North America, and other international markets. The company specializes in developing and marketing treatments for allergic rhinitis and allergic asthma, offering a diverse portfolio of products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK. These solutions target allergies to house dust mites, grass and tree pollen, ragweed, Japanese cedar, and certain foods. The products are available in various forms, including sublingual tablets, injections, and drops, catering to different patient preferences and needs. ALK-Abelló also collaborates with Torii Pharmaceutical Co., Ltd. to develop treatments like GRAZAX for grass pollen allergies and CEDARCURE for Japanese cedar pollen allergies, showcasing its commitment to innovation in allergy care.

Beyond its therapeutic offerings, ALK-Abelló provides diagnostic solutions such as skin prick tests and blood tests to identify specific allergens. The company also offers emergency treatments, including adrenaline injections for severe allergic reactions like anaphylaxis. Additionally, ALK-Abelló has developed a digital ecosystem to engage patients, providing tools, e-commerce solutions, and support throughout the allergy treatment journey. This platform aims to improve patient outcomes by offering personalized guidance and streamlining access to immunotherapy. Founded in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló has established itself as a pioneer in allergy treatment and management.